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1. Introduction 
While in vitro fertilization (IVF) is most often employed as a remedy for infertility, a 
discussion of the field would not be complete if it did not address the application of IVF to 
avoid genetic disorders. IVF makes it possible to assess the genetic status of the embryo 
before establishing a pregnancy when couples are at risk for an affected child. Physicians in 
the field will benefit from being informed about the diverse set of molecular and cytogenetic 
technologies employed in preimplantation genetic diagnosis (PGD) and screening (PGS), 
and from understanding their relative power and limitations as tools for genetic counseling. 
PGD and pre-implantation genetic screening (PGS) refer to two distinct types of clinical 
procedure that help a couple to have a healthy child: PGD determines the embryo’s 
genotype, while PGS assesses an embryo’s karyotype and has been used in screening 
chromosomal aneuploidy. 
PGD and PGS require the use of the IVF technique. These technologies, initiated in the late 
1980s as an alternative to prenatal diagnosis (PND), allows a couple at risk of a genetic 
disorder to give birth to an unaffected child by avoiding selective termination of an affected 
pregnancy. Genetic disorders could be due to either a single gene disorder, or an abnormal 
number or structure of chromosomes. The current agreed upon indications (Cooper & 
Jungheim, 2010) for PGD and PGS include: 
1. Screening for embryo chromosomal aneuploidy in cases of advanced maternal age or 
known parental translocation 
2. Family history indicating risk for known autosomal Mendelian genetic disorders 
3. Sex selection with family history indicating risk for X-linked disorders 
4. Sex selection for family balancing, e.g. parental preference for a male or female 
5. Human leukocyte antigen (HLA) matching to achieve a child to provide hematopoietic 
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The medical need for these services is significant. The U.S. Centers for Disease Control and 
Prevention estimates that more than 6,000 single-gene disorders affect approximately 1 in 
300 live-births (Benson and Haith, 2009), while cytogenetic abnormalities appear at about 
twice this rate in live births and cause approximately ¼ of miscarriages and stillbirths 
(Thiesen & Shaffer, 2010). PGD makes it possible to assess the genetic status of at-risk 
embryos prior to implantation and initiation of a potentially affected pregnancy. There still 
remains considerable controversy regarding the need for and the ability of PGD to increase 
implantation rates for IVF. 
1.1 The milestones of PGD and PGS development 
PGD began in the late 1980's with the pioneering work by Handyside and colleagues in 
selecting embryo gender by polymerase chain reaction (PCR) amplification (Handyside et 
al., 1990), and diagnosis for a recessive autosomal disorder (Handyside et al., 1992). 
PGS was subsequently developed by Munne’s team for gender determination (Munne et al., 
1993), and by Handyside’s team for aneuploidy screening (Schrurs et al., 1993) using 
fluorescent in-situ hybridization (FISH). Other PGD milestones include its application for 
chromosomal translocations (Munne et al., 1998), and for HLA matching that led to the first 
HLA matched baby unaffected with Fanconi anemia (Verlinsky et al., 2001; Grewal et al., 
2004). 
Between the birth of the first PGD baby in 1989 and the year 2000, about 500 babies were 
born worldwide using PGD. Since then, the PGD has been on a steep rise: about 1000 PGD 
babies were born worldwide between 2000 and 2002, and 1500 more PGD babies were born 
between 2002 and 2004 (Verlinsky et al., 2004; ESHRE PGD Consortium, 2002; Harper et al., 
2010). In the past 21 years, while thousands of babies have been born following PGD, there 
are no confirmed reports of increased fetal abnormalities following PGD. 
1.2 Assisted reproductive technologies that support preimplanation genetic testing 
Preimplementation genetic testing is supported by advances in assisted reproductive 
technology (ART). Methodologies of particular importance include intracytoplasmic sperm 
injection (ICSI), laser-assisted biopsies of embryos at the cleavage and blastocyst stages, 
sperm sorting, and cryopreservation of biopsied embryos. 
1.2.1 Intracytoplasmic sperm injection 
In conventional IVF each egg is combined with several thousand motile sperms on the day 
of egg retrieval to fertilize the egg. As a result, numerous sperms are present around the 
fertilized egg. At the next step, embryo biopsy, these excess sperms can contaminate the 
biopsy and contamination of the embryonic sample with sperm DNA can lead to incorrect 
PGD results. To guard against this risk a single sperm can be injected into each egg. This 
procedure is known as intracytoplasmic sperm injection (ICSI; Palermo et al., 1992; Harton 
et al., 2011a). 
Through ICSI eggs are fertilized and embryos are formed. On day 3 of fertilization, a single 
blastomere is removed from each cleavage-stage embryo having 6-8 cells for PGD. When 
embryos develop into blastocysts on day 5 of fertilization, embryos selected by PGD are 
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transferred to the mother. Alternatively, a few cells can be removed from the trophectoderm of 
a blastocyst for PGD on day 5, but the embryo will need to be transferred on day 6. Otherwise, 
the blastocysts need to be stored frozen and transferred at the next fertilization cycle. 
1.2.2 Laser-assisted biopsy of embryos 
PGD is accomplished by evaluating genetic material in polar bodies from unfertilized and 
fertilized oocytes (not performed here), blastomeres from cleavage-stage embryos, or 
trophectoderm cells from blastocysts. Depending on the developmental stage (oocyte, 
embryo or blastocyst), the zona pellucida can be breeched by one of three methods: 
mechanical zona drilling, acidified Tyrodes solution or laser.  
At present, the cleavage stage is most widely used for embryo biopsy, and drilling a hole in 
the zona pellucida with a laser beam is the predominant method (Harton et al., 2011b). On 
day 3 of fertilization when normally developing embroys reach the 8-cell stage, one or two 
blastomeres are aspirated through the opening of a cleavage-stage embryo for PGD using a 
glass capillary pipette. This is also known as blastomere biopsy. 
Biopsy of embryos at the blastocyst stage (on day 5 of fertilization) is more technically 
demanding (Fig. 1). An advantage of blastocyst biopsy is that this procedure is noninvasive 
 
 
Fig. 1. Laser-assisted blastocyst biopsy. Shown in the top and bottom panels before and after 
the removal of a few trophectoderm cells from an embryo at the blastocyst stage for PGD, 
respectively. On day 5 post-fertilization, a few cells excised from the trophectoderm by laser 
beam are aspirated using a glass capillary pipette under stereo microscope. 
www.intechopen.com
 
In Vitro Fertilization – Innovative Clinical and Laboratory Aspects 
 
140 
to the inner cell mass of the embryo because cells are removed only from the trophectoderm 
that will become the placenta. A further advantage is that the removal of multiple cells for 
PGD will significantly lower the allele drop-out (ADO) rate and increase the accuracy of 
testing. A drawback of blasocyst testing is that it allows less time for PGD, and thus the 
embryo may need to be frozen for transfer in the next fertilization cycle if test results are not 
obtained within a day. 
1.2.3 Sperm sorting 
After binding non-intercalating fluorescent dye to their DNA, X- and Y-bearing sperms are 
separated by flow-activated cell sorting based on the difference in total DNA content. The 
purity is greater than 70% for Y-bearing sperms, but greater than 90% for X-bearing sperms. 
Sperm sorting can be used for preconception sex selection used in family balancing, or used 
in combination with IVF-PGD to prevent the transmission of X-linked recessive diseases. 
1.2.4 Cryopreservation of biopsied embryos at the blastocyst stage 
Using the standard freeze-thaw method, the survival rate is low when cleavage-stage 
embryos (on day 3 of fertilization) are biopsied and cryopreserved. The survival rate can, 
however, be improved by vitrification after incubating the cleavage-stage embryos for 6-8 h 
following biopsy (Zheng et al., 2005), or by cryopreservation in CJ3 medium (Stachecki et al., 
2005). Recently higher survival rates of biopsied cleavage-stage embryos have been obtained 
by vitrification at the blastocyst stage (Magli et al., 2006; Zhang et al., 2009). 
2. Current technologies for preimplantation genetic testing 
At the Medical College of Wisconsin and Froedtert Hospital (Milwaukee, Wisconsin, U.S.A.) 
we provide PGD and PDS services for medically indicated conditions (Bick & Lau, 2006; 
Swanson et al, 2007). PGS for chromosomal aneuploidies (monosomy or trisomy) and 
chromosomal translocations is performed by FISH (Swanson et al., 2007). We also provide 
PGD for HLA matching (Bick et al., 2008), diagnosis of specific single-gene disorders 
(Swanson et al., 2007; Lau et al., 2010), and gender selection in cases of X-linked diseases  
(E.C. Lau, K. Wang & M.M. Janson, unpublished). 
For a family with a child who needs bone marrow transplantation, PGD for HLA matching 
(tissue typing) can facilitate birth of an HLA-matched donor infant (Bick et al., 2008; 
Verlinsky et al., 2001). Hematopoietic progenitor cells are then transplanted from cord blood 
or bone marrow of the PGD infant to save the life of the affected sibling. In addition, we 
have developed PGD assays for a few common and/or severe childhood genetic diseases, 
such as spinal muscular atrophy, sickle cell anemia, autosomal recessive polycystic kidney 
disease (ARPKD), and cystic fibrosis. 
2.1 PGD by multiplex PCR 
Single-cell multiplex PCR has been used in the PGD assays for HLA matching, spinal 
muscular atrophy (SMA) and sickle cell anemia. In PGD for these disorders we perform 
multiplex PCR of single blastomeres followed by haplotyping analysis of embryos with 
several linked short tandem repeat (STR) markers (Bick et al., 2008). Multiple markers are 
used due to the high incidence of allele-drop-out for single-cell PCR. 
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In PGD for SMA, we perform multiplex nested PCR of single blastomeres followed by 
restriction cleavage analysis (Swanson et al., 2007). This technique detects the restriction 
fragment length polymorphisms (RFLPs) of the SMN1 and SMN2 genes at exons 7 and 8. 
We use Hinf I for cleaving exon 7 (Daniels et al., 2001), and  Dde I for cleaving exon 8 of the 
SMN genes (Malcov et al., 2004). We use both fast PCR reaction mixture and rapid 
restriction enzymes to shorten the turn-around-time of PGD for SMA (E.C. Lau, 
unpublished). SMA, an autosomal recessive motor neuron disorder, is the most common 
fatal genetic disorder in childhood. It affects 1 in 6,000 to 1 in 10,000 live births, and has 
carrier frequency of 1 in 40 to 1 in 60 in the population. Deletion of both copies of SMN1 
gene accounts for 95% of SMA cases. SMN2 gene is highly homologous to SMN1, but cannot 
substitute for SMN1 gene functions (Prior & Russman, 2011). 
In PGD for sickle cell anemia, we perform multiplex PCR of single blastomeres followed by 
detection of β-globin (HBB) gene mutations by mini-sequencing, which is also known as 
single-base primer extension (Kobayashi et al., 1995; Heinrich et al., 2009). Sickle cell anemia 
is an autosomal recessive disorder caused by single-base mutation in codon 6 of HBB gene, 
that substitutes a thymine for adenine. A conformational change in the hemoglobin S (Hb S) 
molecule reduces its ability to carry oxygen. Other types of sickle cell diseases result from 
co-inheritance of HbS with abnormal globin β-chain variants, such as sickle hemoglobin C 
disease (Hb SC), and sickle β-thalassemia. In PGD for sickle cell diseases, linkage analysis of 
HBB haplotypes is performed with linked STRs located within the HBB gene and its flanking 
regions (E.C. Lau, A.F. Licht & M.M. Janson, unpublished). 
The major drawback of PGD by multiplex PCR is the interaction of PCR primers, which 
results in a long and tedious optimization process to work out a robust mixture for each 
patient family (see Section 3.1). 
2.2 PGD by whole-genome amplification 
A major challenge of PGD is to amplify DNA from single blastomeres and perform 
genotyping analysis within the time constraints of the IVF cycle. In order to meet the turn-
around-time of 30 hours or less for PGD from receiving the biopsied cells to clinical report, 
we have developed a fast and reliable protocol for whole-genome amplification (WGA) 
from single cells using multiple displacement amplification (MDA; Lau et al., 2010). 
Amplification is necessary since a single cell does not contain enough DNA to fulfill these 
assays. 
2.2.1 Techniques for single-cell whole-genome amplification 
The earliest method for whole-genome amplification (WGA) from single cells was PCR-based 
primer-extension preamplification (PEP) of single sperms (Zhang et al. 1992), that was adapted 
for the amplification of single blastomeres in PGD (Sermon et al., 1996). Like other PCR-based 
methods for WGA, the drawbacks of PEP method were incomplete genome coverage, and 
amplification bias (103 to 106 folds) between genomic loci in amplified products. 
More recent technologies for WGA from single cells are multiple displacement amplification 
(MDA; Handyside et al., 2004; Lau et al., 2010; Dean et al., 2002) and PicoPlex® library 
methods. MDA is a non-PCR and isothermal method for DNA amplification. Handyside and 
colleagues used a commercial MDA kit to amplify single blastomeres for PGD (Handyside et 
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al., 2004; Hellani et al., 2004), but the reaction time was 16 hours, and the ADO rates for 
genotyping MDA products were as high as 34%. While commercial kits for MDA are 
optimized for greater than 10 ng input genomic DNA, the use of MDA for WGA of single cells 
is not a standard application supported by the kit manufacturers (Coskun & Alsmadi, 2007). 
We modified the reaction of a commercial rapid-MDA kit for single cells, and obtained 
genotyping results of less than 10% ADO after 4-h MDA reaction (Lau et al., 2010). 
An alternative method for WGA from single cells is the PicoPlex® kit, which is adapted from 
the OmniPlex® technique for genomic DNA (Langmore 2002). The PicoPlex® library kit for 
WGA is a PCR-based technique that requires the fragmentation of large genomic DNA prior 
to the construction of a PCR-amplifiable library. Both MDA and PicoPlex®  methods for 
single-cell WGA have been used in array-based preimplantation testing (Hellani et al., 2008; 
Johnson et al., 2010; see Section 3.1). 
2.2.2 Linkage approach for embryo analysis 
Besides direct mutation detection, we use a linkage approach for embryo and familial 
analysis in PGD. For PGD of single-gene disorders, genotyping analysis is performed for 
embryos using STR markers linked with the disease genes, followed by haplotyping 
analysis. 
“Preimplantation genetic haplotyping” (PGH) is a test procedure for which the first round is 
whole genome amplification (WGA) of single blastomeres, and the second round is 
genotyping using whole-genome amplified products as template. A comparison  of sizes and 
genotypes of STRs among family members allows inferences of the haplotypes for parents and 
an affected child. If the STR loci are closely linked to and flank the disease locus, unaffected 
embryos can be identified by comparing their haplotypes to those of the parents and affected 
sibling. The advantage of using single-cell WGA in the first round of PGD is that a single 
common protocol is used to make many copies of the entire genome for subsequent analysis. 
We have successfully applied PGH to PGD for single-gene recessive disorders, such as 
autosomal recessive polycystic kidney disease (ARPKD; Lau et al. 2010) and cystic fibrosis 
(E.C. Lau, M.M. Janson & T. Boyle, unpublished). ARPKD is caused by mutations in the 
PKHD1 gene, which is located at chromosome 6p12.2 and codes for fibrocystin protein. 
Although 2-5% of all cases of polycystic kidney diseases (PKD) are ARPKD, more than 75% 
of all PKD cases that present clinically in the first month of life are ARPKD, with a mortality 
rate of about 25% in the first month of life (Sweeney & Avner, 2006; Dell & Avner, 2008). 
ARPKD affects approximately 1 in 20,000 live-births, with a carrier frequency of 1 in 70 
individuals. The first PGD case for a family at risk for autosomal recessive polycystic kidney 
disease (ARPKD) was successful using PGH (Lau et al., 2010). A PGD child, whose sibling 
died at birth from the disease and whose parents were both carriers of the gene, was born 
healthy with normal kidneys. 
We have also applied the PGH approach to PGD for cystic fibrosis (CF). CF is the most 
common lethal autosomal recessive disorder among Caucasians of northern European 
ancestry, and is a common genetic cause of infant mortality. The carrier frequency among 
Caucasians in the United States is approximately 1 in 25, but is lower in other racial groups. 
Over 1,000 different mutations in the CFTR gene for CF have been described, but fewer than 
25 occur with appreciable frequency (Amos et al. 2006). 
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PGD for single-gene disorders by PGH is a general approach based on linkage analysis. It 
does not require prior knowledge of the exact nucleotide sites of the mutations within a 
gene. PGH saves the time required to develop custom PGH assays for individual alleles, and 
thus is particularly useful for PGD of single-gene disorders involving many rare or private 
mutations. However, the haplotyping approach for PGD also has limitations. The method 
would be unable to determine the parental haplotypes when the affected child is deceased 
and a DNA specimen is unavailable. In addition, PGH will not infer the correct parental 
haplotypes if the affected inherited a chromosome that had undergone recombination at the 
disease locus (Altarescu et al., 2008). 
2.3 PGD for gender selection 
The application of PGD for gender selection offers an alternative to single-gene assays for 
individual X-linked diseases. Instead of developing custom PGD assays for individual X-
linked diseases, it is more practical to provide a single PGD assay of gender identification 
for families at risk of X-linked diseases. To prevent the transmission of X-linked Mendelian 
recessive diseases, PGD is used to select female embryos offspring. Because two copies of 
the mutant X allele are required for the diseases to occur in females, daughters of unaffected 
fathers will at worst be carriers for the trait. By contast, in males only one copy of the mutant 
X allele is required for the disease to occur and so the male child of a carrier mother has a 
50% risk of having the disease. 
2.3.1 Applications of PGD for gender selection 
The main medical use of PGD for gender selection is to prevent the transmission of X-linked 
Mendelian recessive disorders by giving birth to female offspring. Many X-linked 
Mendelian recessive disorders, such as Duchenne muscular dystrophy (DMD), and 
hemophilia A and B, are rarely seen in females because the child is unlikely to inherit two 
copies of the recessive allele. This may be because the condition is rare, or because affected 
males are reproductively disadvantaged. 
PGD for gender selection may also be used for non-Mendelian disorders that are 
significantly more prevalent in one sex. For the prevention of these inherited disorders, the 
gender of offspring is selected based on the seriousness of inherited condition, the risk ratio 
in either sex, and the options for disease treatment (Amor & Cameron, 2008). 
“Non-medical” applications of PGD for family balancing (also known as “social sexing” or 
“social sex selection”) are more controversial. There is no broad cultural preference for male 
or female offspring in the U.S., but there is a preference of males in some countries, such as 
China, India and the Middle East. This non-medical use of PGD for gender selection and 
family balancing is prohibited in many countries such as China, because it could disrupt the 
sex ratio of the population. 
2.3.2 Method of PGD for gender selection 
We have performed PGD for gender selection by WGA of single blastomeres by MDA, 
followed by multiplex PCR for detecting X- and Y-linked genetic loci (E.C. Lau, M.M. Janson 
& K. Wang, unpublished). The Medical College of Wisconsin and Froedtert Hospital do not 
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support non-medical use of PGD. We provide PGD for gender selection to help families 
with X-linked disorders give birth to unaffected children. 
2.3.3 Sperm separation in combination with PGD for selecting female embryos 
Sperm sorting techniques prior to IVF can be combined with post-fertilization molecular 
diagnosis of the resulting embryos. To prevent the birth of affected children, female 
embryos can be selected by PGD after forming embryos through ICSI with X-bearing sperm. 
For families at risk for rare X-linked recessive disorders, such as Wiskott-Aldrich syndrome 
(WAS) and monocarboxylate transporter 8-specific thyroid hormone cell transporter (THCT) 
deficiency, sperm sorting can be combined with PGD for selecting female embryos instead 
of developing custom PGD assays for these disorders. 
PGD for gender selection can also be used to increase the odds of conceiving an HLA-
matched, unaffected sibling donor. For a family with an X-linked recessive disorder that has 
an affected child in need of a hematopoietic progenitor cell transplant from cord blood or 
bone marrow, the combined use of sperm sorting and PGD for gender selection increases 
the chance of finding an HLA-matched and unaffected sibling donor to approximately 1 in 
5. Otherwise, the chance of finding an HLA-matched female embryo by PGD is only 
approximately 1 in 10. 
2.4 PGS/PGD for cytogenetic anomalies 
Preimplantation screening for cytogenetic anomalies, in particular aneuploidies and 
translocations, has been performed using either FISH probes or array-comparative genomic 
hybridization. We shall discuss the challenges and limitations of both methods. 
2.4.1 Aneuploidy for whole chromosomes 
The adoption of FISH in a preimplantation context was a natural adaptation of FISH 
techniques as used in prenatal diagnosis (PND), where its value in assessing aneuploidy is 
unassailable. In contrast to prenatal specimens, only single, or at most two cells, are 
available for preimplantation genetic testing (PGT), and thus single FISH probe cocktails 
must employ at least 5 fluorochromes to cover the most prevalent liveborn aneuploidies, 
namely, 13, 18, 21, the X and Y. The availability of commercially produced cocktails has 
alleviated the need to “home brew” probes, but has necessitated the acquisition of more 
comprehensive fluorescent filter sets than those used for most routine two- or three-color 
FISH. 
Following biopsy of an embryo the single blastomeres are placed in a hypotonic solution, 
and then treated with acetic acid methanol to fix and spread the cells. All these are 
performed by an embryologist. Ideally this will result in a uniformly flat nucleus with little 
or no overlying cytoplasm. Larger swelled nuclei which have not ruptured and have 
therefore preserved the nuclear contents are desired in order to separate the hybridization 
signals, especially for the large centromere targets, 18, X and Y. Subsequent steps are 
performed in the cytogenetics laboratory. From this point forward a major departure from 
PND, where typically 50 nuclei are assessed, is the reliance on a single nucleus for 
aneuploidy diagnosis. Thus, there is a need for consistency in the fixation and spreading, 
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and freedom from artifacts such as spurious extra signals or weak signals, which are 
inconsequential in multi-cell analyses. 
The partial coverage of a 5-probe set can be partly overcome by sequential hybridizations to 
the same nucleus. The quality and consistency of a second or subsequent hybridization are , 
however, generally progressively inferior due to the damaging hot treatments at 73 oC, 
which are necessary for denaturation and stringent washing. Preliminary indications of 
commercial development of a 6-step reduced-temperature sequential hybridization strategy 
to cover all 24 chromosomes have not to our knowledge been realized, and routine 
widespread use of such a strategy may not be technically realistic. 
Nevertheless, a second hybridization cycle can detect the more common aneuploidies seen 
in early spontaneous pregnancy losses, namely, trisomies 15, 16 and 22. An example of a 
home-brew second cycle is shown in Fig. 2, and utilizes a contrasting color mixture of alpha 
satellite for 15, alpha satellite for 16 and the BCR locus for 22. 
  
Fig. 2. Panel on left is a first cycle of hybridization using Abbott PGT cocktail.  Fluorochrome 
scheme: red = 13, aqua = 18, green = 21, blue = X and Y = gold. This nucleus is euploid for 
these chromosomes and is male. Panel on right is cycle 2 of the same nucleus. Fluorochrome 
scheme: orange = 15, aqua = 16, green = 22, all obtained from Abbott Laboratories. The 
single copy unique sequence BCR is thus the smallest signal. 
From the foregoing discussion one can deduce that several technical difficulties limit the 
usefulness of FISH in aneuploidy assessment. Due to artifactual variation in quality the 
clarity of results seen in Fig. 2 is not always achieved, resulting in ambiguous diagnosis or 
no diagnosis for an embryo. This limitation is inherent to the fact that a single data point 
(FISH signal) in a single nucleus is to be regarded potentially as representative of the entire 
embryo. Secondly, an obvious limitation is the extent of genome coverage, which often 
encompasses only the potentially liveborn trisomies, with a complete absence of information 
regarding other unsampled genomic regions. 
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Both these limitations are overcome by the use of genomic copy number microarrays (see 
Section 3 below). Firstly, each chromosome is represented by many data points by array 
hybridization, making 1, 2 or 3-copy number calls more statistically reliable. Secondly, all 
the chromosomes are represented on arrays, thus all aneupoloides leading to early 
pregnancy loss can be detected. 
2.4.2 Aneuploidy for sub-chromosomal regions 
Arrays using single-cell amplified DNA may not yet be necessarily sensitive enough to 
detect sub-chromosomal aneuploidy. Examples may include small extra marker 
chromosomes or unbalanced segregants of reciprocal translocation, both of which can 
lead to unfavorable pregnancy outcomes. FISH may continue to be of utility in assessing 
aneuploidy from translocation of small but genetically significant regions that have been 
associated with developmental delay or pregnancy loss. We have used a FISH strategy 
when the microarray service cannot provide assurance of reliable coverage of small 
regions. 
An example in our experience is a couple which suffered two pregnancy losses due, in each 
case, to different unbalanced adjacent-1 meiotic segregation products. The small regions 
involved are shown in Fig. 3. 
 
Fig. 3. Balanced t(3;6)(q25.3;p22.2) in a woman with repeated miscarriages and unbalanced 
pregnancy losses. Both unbalanced adjacent-1 products have been observed in karyotyped 
products of conception. 
The probe scheme used to assess their embryos is illustrated in Fig. 4. It also illustrates the 
general rule that labeling three of the four arms of the quadrivalent with probes is necessary 
and sufficient to detect any of the 12 unbalanced products possible, including both adjacent-
1, both adjacent-2 as well as all eight 3:1 segregants. An advantage of translocation FISH 
over aneuploid FISH is that often two data points will mark an unbalanced meiotic product, 
since all adjacent-2 and half of 3:1 products result in a duplication or deficiency for two 
probes. This strategy has been adopted in three pregnancy cycles in the aforementioned 
couple.  
FISH patterns from an embryo clearly unbalanced with an extra 3p signal but a single 6 
centromere are shown in Fig. 5a. This is interpreted as an adjacent-2 segregant, cartooned in 
Fig. 5b. This would result in 3 copies for most of 3 and monosomy for most of 6. 
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Fig. 4. Top, scheme to detect unbalanced t(3;6) meiotic products: subtelomere green (3p) and 
orange (3q) as well as 6 centromere (aqua). Three contrasting probes are sufficient to detect 
all unbalanced products. Bottom, this interphase pattern is balanced, any other pattern is 
unbalanced, following fertilization. 
      
Fig. 5. Left, shows FISH patterns with an extra 3p signal and deficient for a 6 centromere 
signal. This is one of two cells from this embryo showing adjacent-2  segregation. Right, 
depicts this unbalanced complement.  
To date adjacent-1 and adjacent-2 segregants have been detected in this couple, including 
those equivalent to both of the previous cytogenetically documented pregnancy losses. 
It should be emphasized that both FISH and microarray approaches are limited in predictive 
value by strictly biological considerations. It is apparent by numerous studies that many 
early embryos are mosaic for aneuploidy. In addition, mosaic embryos often “correct”, 
leading to normal outcomes following an aneuploid finding based on a single cell (Barbash-
Hazan et al, 2009). Thus, both false negative and false positive findings may be expected 
3 6p q 
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from these single cell approaches. These considerations must be kept in mind when 
counseling couples to the value and accuracy of anueploid PGD. 
3. Technological advances in preimplantation genetic testing 
Robust WGA protocols (see section 2.2 above) and high-throughput DNA technologies such 
as microarrays and next generation sequencing (NGS) make it reasonable to envision PGD 
by interrogating the complete genome of a single blastomere. Completing a whole-genome 
analysis within the time frame of an IVF cycle via either technology remains a technical 
challenge. Genomic strategies, however, offer the promise of universal diagnosis and 
screening methods with consequent advantages in cost efficiency and diagnostic power. 
Emerging technologies for whole genome analysis via DNA microarrays and DNA 
sequencing are rapidly becoming more powerful and more cost effective, and it will soon be 
feasible to apply these genomic tools widely in reproductive medicine. 
3.1 PGD/PGS by microarrays 
DNA microarray technologies measure hybridization between the subject’s DNA (the 
“target”) and a matrix of known DNA sequences (the array “features”) immobilized on a 
solid state matrix. Depending upon the array platform and hybridization protocol, 
microarrays can reveal gains or losses of genome segments or determine the subject’s 
genotype for SNPs. 
Array-comparative genomic hybridization (aCGH) has become an established alternative to 
FISH for PGS of aneuploidies, unbalanced translocations and complex karyotypes with 
multiple rearrangements (Hellani et al., 2008; Van den Veyver et al., 2009; Harper & Harton, 
2010; Alfarawati et al., 2011; Fiorentino et al., 2011; Vanneste et al., 2011). In this procedure, 
target and control genomic DNAs are mixed and competitively hybridized to the same 
array. Changes in the hybridization ratio of target to control at a region indicate a gain or 
loss of material relative to the control genome. Since aCGH interrogates every chromosome 
and reveals events below the limits of microscopic detection, it is able to identify 
chromosome anomalies that a standard 8- or 12-chromosome FISH might fail to detect. 
However, aCGH does not detect balanced rearrangements or triploidy, where the 
target:control DNAs hybridized to the array features is constant along the genome 
(Thornhill et al., 2008; Harper & Harton, 2010; Fiorentino et al., 2011). 
Single-gene disorders are amenable to whole-genome analysis using SNP microarrays. The 
SNP array features include alternative alleles for a large number of polymorphisms, and 
hybridization indicates which SNP allele(s) are present in the target genome. The SNP 
genotypes of two parents and a reference child define maternal and paternal haplotypes at a 
gene of interest, and linkage then establishes the genetic risk for a second child based on its 
combination of parental haplotypes. The analysis is similar to STR haplotyping discussed 
previously (see section 2.2.2). While custom PGD linkage assays have been developed for 
less than 10% of the known single gene disorders, a single microarray generates predictive 
SNP haplotypes for the entire genome. 
Handyside et al. (2010) employed SNP genotype data to create “karyomaps” that represent 
the parental haplotypes and points of recombination along a child’s chromosomes. In this 
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work, SNP haplotypes were shown to coincide with the inheritance of cystic fibrosis in 
families where both parents were carriers for CFTR mutations (Handyside et al., 2010). 
Unpublished results from our laboratory (C.B. Ball & E.C. Lau) also serve as support the 
concept of SNP haplotyping for Mendelian disorders. SNP haplotypes linked to eleven loci 
of clinical interest were analyzed in a family of four individuals. At each locus, a region 
comprised of the gene of interest and 2 Mb flanking on either side contained sufficient 
informative SNPs to infer paternal and maternal haplotypes and predict the genetic status of 
a sibling to the reference child. We validated the SNP haplotypes analysis with PCR assays 
for STRs linked to three of the eleven loci (see section 2.2.2). Table 1 (a and b) summarizes 
the findings for these three genes: 
(a) SNP haplotypes linked to loci of interest and diagnosis for proband child. 
Locus 
Linked SNPs SNP Haplotypes # of SNPs 
matching 





CFTR 903 255 P1 P2 M1 M2 P1  M1 P2 M2 245 / 253 
HBB 1,747 528 P1 P2 M1 M2 P1  M1 P1 M2 499 / 528 
PKHD1 1,492 488 P1 P2 M1 M2 P1  M1 P1 M2 472 / 488 
(b) STR haplotypes linked to loci of interest and diagnosis for proband child. 
Locus STR location 
STR haplotypes




















































Table 1. Comparison of haplotyping for SNPs linked to three clinically significant loci (a) 
with haplotyping for STRs linked to the same loci (b). 
It should be noted that of 21 custom primers tested, only five assays were informative in this 
pedigree (Table 1b). This illustrates the universality of SNP genotyping compared to STR 
methods and the value of avoiding custom assays. 
SNP arrays are also of value in assessing aneuploidy and unbalanced chromosome 
rearrangements. Johnson et al. (2010) showed that integrating SNP genotype data with copy 
number improved the quality of analysis for noisy data such as those obtained from single-
cell WGA. Similarly, Handyside et al. (2011) established that karyomapping across the 
whole genome would detect chromosome imbalances and identify the parent of origin for 
the imbalance based on the parental genotypes. 
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3.2 Future PGD/PGS by DNA sequencing 
Besides high-density microarrays, SNPs can be detected genome-wide by DNA sequencing, 
which provides genotyping analysis at the highest resolution. For PGD of single-gene 
disorders, DNA sequencing would be the future method of choice. The assay can interrogate 
the entire genome, or target specific regions and genes of special interest. In principle, 
sequencing methods can search directly for a targeted base change, or generate SNP 
haplotypes for a linkage-based diagnosis. Second-generation sequencing systems, such as 
Roche 454 system, Illumina sequencers and ABI SOLiD system, have not been used for PGD 
due to the high cost and slow turn-around-time. 
Even if the cost of whole genome DNA sequencing falls to $1,000, it is still too costly for 
routine clinical PGD when the total cost of sequencing the parental samples, affected child 
and several embryos is considered. In contrast to accurately determining the genotypes of 
every SNP that requires sequencing at high genome coverage, it may lower the cost of PGD 
using a haplotying approach that would require a lower genome coverage to identify the 
SNP haplotypes of embryos for transfer.  
The recently released third-generation DNA sequencers, such as the Single-Molecular Real-
Time System RS (Pacific Biosciences, CA), has enabled more rapid and cost effective 
genomic sequencing. Future sequencing technologies, such as DNA transistor nanopore 
sequencing system (Roche-IBM), and DNA tunneling silicon nanopore sequencer, will 
benefit PGD when the sequencing cost falls below $250, and the turn-around-time to be less 
than 24 hours. 
4. Genetic counseling for PGD/PGS 
Genetic counseling is an essential step for patients contemplating PGD (Swanson et al., 
2007). During the counseling session information is gathered including the patient’s medical 
and reproductive history, the partner’s medical and reproductive history, and their family 
histories. Both the patient and her partner should attend the counseling session. If an 
indication of risk is not covered, it is essential that the counselor obtains the physician 
and/or laboratory records supporting the information. Preimplantation genetic testing 
should not be undertaken without a firm diagnosis. With this information in hand the 
counselor can discuss disorder(s) in the family, the severity and variability of such 
condition(s), limitations of genotype/phenotype and the patient’s probability of affected 
children. All of this information will help a patient decide whether PGD would be a 
reasonable option for her situation. 
If PGD appears to be an option, then information is provided detailing the testing that can 
be carried out on single embryonic cells. Limitations of such testing are discussed including 
the patient’s anticipated success rate for IVF with PGD and the possibility of both false 
positive and false negative PGD results. Prenatal testing through chorionic villus sampling 
(CVS) or amniocentesis is recommended to confirm the results of PGD. Patients should be 
reminded of alternative reproductive options including use of donor gametes, prenatal 
diagnosis (PND), accepting genetic risk without further testing, adoption, and having no 
children or no additional children (Harton et al., 2011c). 
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By combining the information from the reproductive medicine specialist and the genetic 
counselor, the patient can decide whether to pursue PGD. It is important that the counseling 
provided should be non-directive, to enable the patient to reach her own conclusion about 
the suitability of PGD (Shenfield et al., 2003). 
5. Future prospects for preimplantation genetic diagnosis 
Severe genetic disorders are debilitating, expensive and incurable conditions. The patient, 
the family and society at large each have an interest in avoiding the birth of a child with 
such a disease. PGD provides that option in a cost-effective manner, without resort to 
termination of an affected pregnancy. 
5.1 Current status of choice between PGD/PGS and PND in the U.S. 
Prenatal diagnosis (PND) of fetuses is performed by either amniocentesis or CVS performed at 
different stages of fetal development, but the procedures are invasive and parents may 
ultimately decide to terminate an affected fetus. Even though PGD has been available for 21 
years, PND following natural conception still prevails in the U.S. For couples at risk of severe 
inherited genetic disorders, abortion of affected pregnancy is still the most common option, 
especially in those States which do not have mandatory insurance coverage for IVF and PGD. 
5.2 Medical and economic considerations of universal access to PGD/PGS 
The medical community has recently begun to address the medical and economic 
implications of implementing a national PGD program to help couples who are carriers of 
severe single-gene disorders.  
About 1000 children affected with cystic fibrosis (CF) are born annually in the U.S., in some 
part due to reluctance to terminate affected pregnancies. There is the potential to save 33 
billion dollars in lifetime medical care for those affected with this disorder if carrier parents 
had the option of undergoing government-backed or insurance-mandated PGD and IVF 
(Tur-Kaspa et al., 2010). For couples who are carriers of severe inherited genetic disorders, 
prevention of affected pregnancy by PGD may be a preferred option to the termination of 
affected fetuses (Davis et al., 2009). Thus, economic and medical considerations favor a 
universal and affordable access to IVF, PGD or PGS services for carrier couples of severe 
single-gene disorders such as CF, or for individuals at risk for transmitting chromosomal 
translocations, but cannot afford it (Handyside, 2010). 
6. Ethical concerns 
The non-medical use of PGD and PGS presents some ethical concerns. While PGD has mainly 
been used to select embryos unaffected with severe genetic diseases to avoid the transmission 
of some medical conditions, PGD may also have the potential to select an embryo affected 
with the same disability or disease that affects the parents, such as deafness. A deaf child born 
to a deaf couple would be better suited to the parents' shared culture. 
There is resistance regarding the practice of reproductive technologies including IVF, PND, 
abortion, sperm sorting, PGD/PGS, and embryonic stem cells. In fact, many countries have 
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banned the use of PGD for gender selection, but it is permitted in the U.S. The opponents of 
“social sex selection” argue that the consequences of preimplantation procedures such as 
sperm sorting, PGD and PGS would artificially unequalize the ratio of females to males. The 
opponents of PGD and PGS fear that these technologies could be used for eugenic purposes, 
or increasing uses of PGD may open the door to other eugenic technologies.  
PGD has successfully been used to prevent the transmission of single-gene disorders with 
Mendelian inheritance, but has not been used for complex genetic disorders because there is 
insufficient amount of amplified DNA from a single blastomere with high fidelity for testing a 
large number of genes and single-nucleotide polymorphisms (SNPs). Complex genetic 
disorders (e.g. diabetes mellitus), athletic ability and intelligence are controlled by many genes 
and environmental factors. Similarly, physical traits (e.g. body height), and cosmetic traits (e.g. 
hair color, eye color and skin pigmentation) are determined by multiple genes and SNPs 
(Sulem et al., 2007). With the recent advancement in blastocyst biopsy for removing multiple 
cells, cryopreservation of blastocysts, whole-genome amplification methods that generate  
amplified DNA with high fidelity, it has been technically feasible to provide preimplantation 
testing for complex genetic disorders and human traits. When PGD expands its scope to such a 
non-medical realm in potential attempts to make “designer babies”, it will spark more debates 
and controversy that might lead to legislation in this area. 
7. Conclusion 
Preimplantation genetic testing is an important application of IVF and has broad interest to 
reproductive medicine practitioners. Economic and medical considerations favor a universal 
and affordable access to IVF and PGD/PGS services for carrier couples of severe inherited 
genetic disorders. In addition to current methodologies, preimplantation testing is an 
expanding field poised to adopt cutting-edge genomic technologies for new advances in 
preventative medical care. Technologies for interrogating whole genomes via via SNP 
microarrays microarrays and DNA sequencing are rapidly becoming more powerful and 
more cost-effective. It will soon be feasible to apply these genomic tools widely in 
reproductive medicine. 
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aspects of this field. This work is a result of collaborative work of an international group of professionals
dedicated to contribute to the advancement of our knowledge.
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